Boston Scientific price target raised to $56 from $53 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Boston Scientific (BSX) to $56 from $53 and keeps an Overweight rating on the shares. The company delivered a "very robust beat" in Q1, growing sales at two-times the consensus, but news reports last week citing buyout talks with ShockWave Medical (SWAV) "have kept investors on edge," the analyst tells investors in a research note. The firm says Boston Scientific’s avoidance of the topic on the earnings call stopped short of dismissing the idea outright, leaving investors with the feeling that "not saying ‘no’ might mean ‘maybe.’"